Replimune Reports Widening Losses and Shortened Cash Runway Amidst Regulatory Progress

summarizeSummary

Replimune Group reported a substantial increase in its annual net loss and a reduced cash position, with its cash runway now extending only into the first quarter of 2027, despite recent positive regulatory updates for its lead drug candidate RP1.

check_boxKey Events · Earnings and Guidance · REPL

• Increased Net Loss

  The company reported a net loss of $313.9 million for the fiscal year ended March 31, 2026, a significant increase from $247.3 million in the prior fiscal year.

• Reduced Cash Position and Runway

  Cash, cash equivalents, and short-term investments decreased to $268.9 million as of March 31, 2026, down from $483.8 million a year prior. This cash position is expected to fund operations only into Q1 2027.

• Higher Operating Expenses

  Research and development expenses rose to $221.2 million for fiscal year 2026, and selling, general and administrative expenses increased to $98.7 million, reflecting scaling operations.

• Regulatory Update Reiteration

  The filing reiterates that the FDA has accepted the resubmission of the Biologics License Application for RP1 in advanced melanoma, with a goal date of August 2, 2026, and an advisory committee meeting expected in late July. This news was previously announced on June 26, 2026.

auto_awesomeAnalysis · REPL · Life Sciences

Replimune's latest financial results reveal a significant increase in net loss and cash burn for fiscal year 2026, leading to a cash runway projected only into Q1 2027. This financial deterioration is a major concern for investors, despite the positive reiteration of the FDA's acceptance of the RP1 BLA resubmission and an upcoming advisory committee meeting. The company's ability to fund operations beyond early 2027 will likely require further capital raises, which could be dilutive.